Resistance of Plasmodium spp. to anti-malarial drugs is the primary obstacle in the fight against malaria, and molecular markers for the drug resistance have been applied as an adjunct in the surveillance of the resistance. In this study, we investigated the prevalence of mutations in pvmdr1, pvcrt-o, pvdhfr, and pvdhps genes in temperate-zone P. vivax parasites from central China. A total of 26 isolates were selected, including 8 which were previously shown to have a lower susceptibility to chloroquine in vitro. For pvmdr1, pvcrt-o, and pvdhps genes, no resistance-conferring mutations were discovered. However, a highly prevalent (69.2%), single-point mutation (S117N) was found in pvdhfr gene. In addition, tandem repeat polymorphisms existed in pvdhfr and pvdhps genes, which warranted further studies in relation to the parasite resistance to antifolate drugs. The study further suggests that P. vivax populations in central China may still be relatively susceptible to chloroquine and sulfadoxine-pyrimethamine.
Among the 5 species of Plasmodium parasites that affect hu mans, Plasmodium vivax is the most widely distributed and cau ses a serious public health burden [1, 2] . In central China, the transmission of malaria is entirely due to P. vivax. Since 2000, vivax malaria has demonstrated resilience to eradication and has become increasingly prevalent in this region, especially in areas along the Huai River [3] . Control measures of vivax ma laria are confounded by 2 major factors; dormant hypnozoite stages in the liver, and the emergence of drug resistance. Che motherapy remains a key factor in the fight against malaria. The tools that are used to monitor drug efficacy include clini cal trials, in vitro studies, and molecular markers for detection, each of which made important contributions to a more com plete understanding of antimalarial drug resistance. In a pre vious study, the susceptibility of P. vivax to antimalarial drugs was observed by in vitro testing [4] , though further investiga tions are needed to assess the predictive value of molecular markers in central China.
Molecular markers of drugresistant P. vivax, including mu tations in multidrug resistance 1 gene (pvmdr1) and putative transporter protein CG10 gene (pvcg10 or pvcrt-o), which are orthologous to pfmdr1 and pfcrt-o genes, respectively, have been identified as possible genetic markers of chloroquineresistance (CQR) [5, 6] . The genotypes of dihydrofolate reductase (pvdhfr) and dihydropteroate synthase (pvdhps) have been determined, and their association with the clinical response to sulfadoxine pyrimethamine (SP) has been confirmed [710] . The sequenc es which result in amino acid changes of these genes vary de pending on the geographic area, and an increasing number of specific mutations results in higher levels of resistance. Chloro quine resistance is associated with single nucleotide polymor phisms (SNPs) in pvmdr1 at codon (c) 976 (Y976F) [11] and pvcrt-o at c10 (K10 insertion). Also, SNPs at c57 (F57L), c58 (S58R), c61 (T61M), and c117 (S117N) in pvdhfr are associated with pyrimethamine resistance [12, 13] , while sulfadoxine re sistance is associated with SNPs at c382 (S382A/C), c383 (383G), and c553 (A553G) [12] . This study aimed to fill some of the gaps in our knowledge of susceptibility to commonly used an timalarials, and hence, the prevalence of genetic polymorphi sms in P. vivax drug resistanceassociated genes, including pvmdr1, pvcrt-o, pvdhfr, and pvdhps, were evaluated using isolates from central China.
Based on the completed wildtype sequences, including nu cleotides, the amino acid sequences and SNPs reported in the target genes were analyzed; GenBank accession nos. AY571984 for pvmdr1 [14] , AF314649 for pvcrt-o [15] , X98123 for pvdhfr [8] , and AY186730 for pvdhps [10] . According to the reported SNP results, the target sequences of each gene were selected for PCR amplification and sequencing, covering the resistancecon ferring mutations of each gene. Samples, determined to be pos itive for P. vivax by microscopy, were collected from local hos pitals and Centers for Disease Control and Prevention (CDC) in central China from 2005 to 2008. Ethical approval was ob tained from the ethical review committees at the National In stitute of Parasitic Diseases, Chinese CDC, and the Walter Reed Army Institute of Research, USA. Filter papers with whole blood deposits were used for DNA elution by methods described pre viously [16] . To avoid crosscontamination, punch was cleaned in 70% ethanol and then punched a clean filter paper 3 times before cutting a new sample. During the process, measures were taken to prevent crosscontamination.
Amplifications of target gene fragments were performed by PCR using 2 µl of 10× PCR buffer (10 mM TrisHCl, 50 mM KCl, pH 8.3), 2.5 mM MgCl2, 0.2 mM of each dNTP, 0.25 µM of each primer, 0.5 U of AmpliTaq Gold DNA polymerase (Ap plied Biosystems, Foster City, California, USA), and 1 µl of ge nomic DNA or the amplicon from the first PCR. Amplifications were carried out in a GStorm GSI thermal cycler (Gene Tech nologies Ltd, Somerton, England) in a final reaction volume of 20 μl. The cycle conditions were an initial denaturation at 94˚C for 10 min, followed by 35 cycles of denaturation at 94˚C for 50 sec, annealing at primer dependent temperature for 1 min, and extension at 72˚C for 11.5 min. The genespecific primers for amplifications were used as described previously (Table 1) . Among them, primers set F1/R1 were used for the firstround PCR to amplify the pvdhps gene, and F2/R2 were used for the secondround PCR. The purified PCR products were sequenced with the sequencing primer using the ABI PRI SM 310 Genetic Analyzer and a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). The deduced amino acid sequences were aligned and analyzed with Lasergene® software (DNASTAR, Madison, Wisconsin, USA). Amino acid sequences were compared with the reference wildtype sequences, where insertions and deletions were verified manually.
The pvmdr1 has an openreading frame (ORF) of 4,392 base pairs (bp) encoding a protein of 1,464 amino acids (aa). Pvcrt-o coding sequence extends across 14 exons, which range from 45 to 266 bp, each of the exon contains part of the ORF. The whole pvdhfrts gene was composed of an exon with 1,872 bp (623 aa) and a short tandem repeat region (262309 bp). The DHFR and TS domains of the gene with a linkage sequence of 100 aa encode 237 and 286 aa residues, respectively. The pvdhps gene consists of 2,591 bp, including the ORF sequence 2,196 bp (731 aa) which includes 3 exons, nucleotides 1127, 374 2326, and 2,4762,591 bp, respectively. The reported codon mutations of each gene were indicated, and resistanceconfer ring mutations were marked with red color (Fig. 1) .
Based on the reported results, fragments of pvmdr1 (expected amplicon sizes are 604 bp), pvcrt-o (1,186 bp), pvdhfr (716 bp), and pvdhps (1,301 bp) were selected for amplification (Fig. 1) . A total of 26 P. vivax single infection samples were selected for this study, including 8 samples collected in Bengbu, Anhui Province during 20052006, which had shown lower suscepti bility to chloroquine in a previous in vitro study [4] , as well as 18 further samples collected in Suining, Jiangsu Province dur ing 2008. The history of antimalarial drugs used in these 2 sites was similar, and Suining is located in the border of the 2 provinces. The pvmdr1 gene was successfully sequenced in all 26 isolates. Compared with Salvador I as the reference wildtype, mu tant alleles at position 1076 (F1076L) were present in all iso lates, wildtype c976 (Y976) was observed in all isolates, and no other nonsynonymous or synonymous mutations were found ( Table 2 ). The pvcrt-o gene was successfully sequenced in 84.6% (22/26) of the selected isolates, including 8 samples collected in 20052006 and 15 samples collected in 2008. Of the target fragment of the pvcrt-o gene that was sequenced, only wildtype was observed, and the K10 insertion (AAG) did not exist in any of the isolates tested ( Table 2) . As pvmdr1, the pvdhfr gene was also successfully sequenced and analyzed from all 26 selected isolates. Compared with the wildtype sequence, nonsynonymous mutations were detected only at residues 99 and 117. The point mutation at c99 was localized in the short tandem repeat region. The central tandem repeat region be tween amino acid positions 88 and 105 of the pvdhfr gene also exhibited size polymorphism in a number of 18 bp repeats.
A total of 23.1% of the samples showed a pattern in the re peat region similar to that in the wildtype. The remaining sam ples identified as having deletion mutations and previously re ported H99S mutations accounted for 65.4% and 11.5%, re spectively. The deletion genotype within the pvdhfr tandem re peat region had the deletion at position 98103 (THGGDN). The pvdhfr mutant allele at c117 (S117N) was observed in 18 isolates (69.2%) ( Table 2 ). The pvdhps gene was successfully amplified and sequenced from 23 parasite isolates, including 6 samples collected in 20052006 and 17 samples collected in 2008. In contrast to the pvdhfr gene, no SNP was present in pvdhps except for the tandem repeat variation (spanning 603 665 aa). Length polymorphism of the sequence was observed for a variable number of tandem repeat unit G(E/D)(A/G/S) KLTN, and the samples were identified as 2 kinds of mutation types. The 2 repeat haplotypes were reported previously [17] . The most common haplotype represented 95.7% (22/23) of the analyzed samples and appeared to be different from the reference wildtype strain by only 1 mutational step. Another haplotype was only present in 1 sample, which was different to the wildtype in the tandem repeat unit and number ( Table  2 ). The sample with the rare type of tandem repeat in the dhps gene was identified as having the wildtype dhfr tandem repeat 
R; repeat region GGDN/TSGGDN/THGGDN (C) and GEAKLTN-GEGKLTN-GEAKLTN-GEGKLTN-GEAKLTN-GEGKLTN-GDAK-LTN-GDSKLTN-GEAKLTN (D).

Including 2 types with the sequences of GEAKLTN-GEGKLTN-GEAK-LTN-GEGKLTN-GDAKLTN-GDSKLTN-GDSKLT-GEAKLTN (4.3%, 1/23) and GEAKLTN-GEGKLTN-GEGKLTN-GEAKLTN-GEGKLTN-GDAKLTN-GDSKLTN-GEAKLTN (95.7%, 22/23).
region. No relationship was observed between the mutations in the sequenced genes and the period of isolate collection.
As the most frequent and widely distributed cause of recur ring malaria, P. vivax infection represents a considerable part of malarial disease as well as an economic burden in China, especially in the central region. In China, the action plan for malaria elimination was initiated by the Chinese government in 2010; however, the predominant malaria parasite P. vivax is among the biggest challenges facing the elimination programs. Several possible factors cocontributed to the reemergence of the disease, including emergence of drug resistance and global warming, and hence, it is important to increase research efforts for understanding the epidemiology of P. vivax in this area.
According to the antimalarial drug policy of China, the first line therapies for vivax malaria treatment are currently chloro quine plus primaquine during the past 60 years. Clinical resis tance to pyrimethamine, used for malaria prophylaxis, was first reported in temperatezone provinces in the late 1970s [18, 19] , though recent studies suggest that this family of drugs may find a role in the future treatment of P. vivax malaria in certain re gions [20, 21] . With the emergence of CQR P. vivax strains in many malarious regions, including the report of treatment fail ure by chloroquine in 4 cases of P. vivax malaria in Yunnan Province [22] , it became a much higher priority to monitor drug resistance and develop new drugs for future treatment of P. vivax malaria. However, there has been no conclusive evi dence showing the emergence and spread of CQR P. vivax in central China until now.
In a previous study, we investigated antimalarial suscepti bility of P. vivax in this temperatezone by in vitro testing [4] , and a variety of antimalarial drugs with potential clinical use in China were tested. The results indicated that for P. vivax iso lates from this area, the IC50s of chloroquine were lower than those of isolates from South Korea and Thailand. Reduced sus ceptibility to pyrimethamine was also observed, compared to isolates from Thailand, but a greater sensitivity was observed in isolates from South Korea. Four patients from the same area were enrolled in the study, each of which had parasites with higher in vitro IC50s, suggesting the presence of clinical resis tance to chloroquine in this area. The molecular data for pvmdr1, pvcrt-o, pvdhfr, and pvdhps in this study could provide use ful information about drug resistance in P. vivax isolates from central China.
Although the mechanisms of CQR in P. vivax are not very clear, 2 main transporters have been studied with regard to CQR in P. vivax, including pvcrt-o and pvmdr1, indicating that the amino acid polymorphisms were associated with chloro quine resistance [9, 10] . In our study, pvmdr1 Y976F mutation and K10 insertion in the pvcrt-o gene were not found in all of the isolates tested, including those which had shown higher chloroquine IC50 values through an in vitro drug sensitivity study. Thus, it is indicated that CQR may not yet be prevalent in central China as had been previously thought. The point mutation pvmdr1 F1076L, which has been suggested to be a neutral allele [23] , existed in all isolates tested.
The resistance mechanism of P. vivax to antifolates has been proposed to be similar to that of P. falciparum, which has been linked to mutations at homologous positions in pvdhfr and pvdhps [1114] . Results from in vitro drug assays and clinical assessments are generally agreeable with this assumption [12, 2427] , suggesting that molecular genotyping data for pvdhfr and pvdhps could provide useful information about SP resis tance in P. vivax. Our study showed that mutant pvdhfr geno types were present at relatively high levels, but the resistance conferring mutations only occurred at a single c117N. Two mu tant genotypes at residue 117 (S117N and S117T) have been reported in areas with extensive SP drug treatment [10, 28] and only S117N was observed in this study. The S117N mutation has been hypothesized to represent the first step in the drug resistance selection process in the parasite [29] . In contrast, S117T has been associated with highly mutated pvdhfr, which may be a key mutation for subsequent acquisition of addition al mutations and development of high resistance to SP [11, 29] . Consistent with these, highly mutated pvdhfr (double, triple, or quadruple mutations) was not observed in this study. Similar to a previous report, no resistanceconferring mutations were found in pvdhps gene among all of the isolates examined in this study. It has been proposed that the development of resis tance mutations in dhfr and dhps of P. vivax is asynchronous, and mutations in dhfr appear to be selected before those in dhps [25, 30] . The present study showed that resistanceconfer ring mutations were found in pvdhfr but not in pvdhps and thus further validated this hypothesis. The results suggest that the P. vivax parasites in central China may be still relatively suscepti bility to SP.
A tandem repeat sequence is one of the unique features in the pvdhfr, which is absent in P. falciparum and P. chabaudi. The isolates examined in this study were typically separated into 2 types, deletion (nucleotides 292309) and mutation H99S in pvdhfr, with the exception of 6 wildtype isolates. Both types of the tandem repetitive sequence did not appear to be clearly as sociated with a specific genetic profile, and no relationship was found between the type of c117 and the repeat. A similar repeat motif has also been described in pvdhps gene [31, 32] , which has been predicted not to directly bind sulfa drugs, and there fore is unlikely to be involved in resistance to sulfa drugs in P. vivax. No wildtype of the tandem repeat sequence was deter mined in the pvdhps gene in this study. They were typically se parated in 2 types also, although 1 type (95.7%) was mainly observed. Both of these tandem repeat sequences showed size polymorphisms, which may indicate a lack of SPselective sweep in these parasite populations, and warrants further studies of the parasite resistance to antifolate drugs.
Resistanceconferring mutations in pvmdr1, pvcrt-o, and pvdhps genes were not discovered, but a single point mutation in pvdhfr gene was common to both studies. Comparing the results with isolates from SouthEast Asia, temperate P. vivax strains show much lower polymorphisms in these drugresistance genes, consistent with the drugs pressure in these areas [28, 33] . Although the number of samples used in this study was limit ed, isolates which had shown a likelihood of drugs resistance were selected, and the results were shown to be comparable to other studies in central China [17, 25, 34] . Analysis of the SNPs of drugresistance genes has been proven to be useful and im portant in monitoring drug resistance in malaria endemic coun tries and should be investigated thoroughly. 
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